Adjuvant PD-1-based therapies for high-risk resected melanomas are here to stay
Authors:
- 1 June 2024
- journal article
- editorial
- Published by Elsevier in The American Journal of Surgery
- Vol. 235, 115791
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Cutaneous melanomaThe Lancet, 2023
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaNew England Journal of Medicine, 2023
- Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trialsAnnals of Oncology, 2023
- Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialNature Medicine, 2022
- Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaCancer Discovery, 2022
- Circulating Tumour DNA in Melanoma—Clinic Ready?Current Oncology Reports, 2022
- Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive MelanomaCancers, 2021
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609Journal of Clinical Oncology, 2020
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017